生物活性：Lidocaine-d6 (hydrochloride) is deuterium labeled Lidocaine (hydrochloride). Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor[2].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Lidocaine-d6 hydrochloride 相关抗体:
MEK1/2 Antibody
ERK1/2 Antibody
Phospho-ERK1/2 (Thr202/Tyr204)/(Thr185/Tyr187) Antibody
NF-KB p65 Antibody
Phospho-ERK1/2 (Thr202/Tyr204)/(Thr185/Tyr187) Antibody (YA455)
Phospho-NF-KB p65 (Ser536) Antibody
E-Cadherin Antibody (YA470)
Fatty Acid Synthase Antibody (YA766)
DYKDDDDK Tag (FLAG) Antibody
GAPDH Antibody
GFP Antibody
p53 Antibody (YA250)
RUNX2 Antibody
Phospho-NF-κB p65 (Ser529) Antibody
Ferritin Heavy Chain Antibody
COX2 Antibody
Ctip2 Antibody
Cyclin D1 Antibody (YA485)
Cytochrome C Antibody
NF-KB p65 Antibody (YA267)
ERK2 Antibody
c-Myc Antibody
Cyclin E1 Antibody
Phospho-MEK1 (Ser298) Antibody
xCT Antibody (YA006)
AIF Antibody (YA636)
ALIX Antibody
CNPase Antibody
Cortactin Antibody
COX IV Antibody
分子量：276.84
Formula：C14H17D6ClN2O
CAS 号：2517378-96-8
非标记 CAS：73-78-9
中文名称：盐酸利多卡因-d6
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (535 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11.
 [Content Brief]
[3]. Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233.
 [Content Brief]
[4]. Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):31-6.
 [Content Brief]